2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Cancer of Prostate in 94 studies
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here we demonstrate that in human prostate cancer cells, basal-, growth factor-, and mitogen-induced expression of hypoxia-inducible factor 1 (HIF-1) alpha, the regulated subunit of the transcription factor HIF-1, is blocked by LY294002 and rapamycin, inhibitors of PI3K and FRAP, respectively." | 5.31 | Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. ( Chiles, K; Feldser, D; Georgescu, MM; Hanrahan, C; Laughner, E; Semenza, GL; Simons, JW; Zhong, H, 2000) |
| "Artemisinin treatment induced the 26S proteasome-mediated degradation of the receptor protein, without altering AR transcript levels, in androgen-responsive LNCaP prostate cancer cells or PC-3 prostate cancer cells expressing exogenous wild-type AR." | 1.46 | Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein. ( Aivaliotis, VI; Firestone, GL; Steely, AM; Sundar, SN; Willoughby, JA, 2017) |
| "Castration-resistant prostate cancer cells often develop resistance to chemotherapy agents and the search for new therapeutic strategies is necessary." | 1.43 | Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation. ( Castilla, C; Flores, ML; Gasca, J; Japón, MA; Medina, R; Pérez-Valderrama, B; Romero, F; Sáez, C, 2016) |
| "Four human prostate cancer cell lines (LNCaP, LNCaP95, VCaP and 22Rv1) with different genetic backgrounds were treated with five PI3K/AKT inhibitors (LY294002, Wortmannin, BKM120, AKTi and AZD5363) and or AKT siRNA." | 1.40 | Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells. ( Dong, X; Liu, L, 2014) |
| "Transition of prostate cancer (PC) to the castration-resistant phenotype correlates with AR-V7 accumulation, suggesting that PC progression in patients refractory to conventional therapy is due to the activity of this AR isoform." | 1.39 | The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. ( Hartig, SM; Hayes, TG; Mancini, MA; Marcelli, M; Mediwala, SN; Sonpavde, G; Sun, H; Szafran, AT; Thiagarajan, P, 2013) |
| "Here we show in 1-LN prostate cancer cells that 8-CPT-2Me-cAMP causes a dose-dependent increase in Epac1, p-Akt(T308) , p-Akt(S473) , but not p-CREB." | 1.38 | Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex. ( Misra, UK; Pizzo, SV, 2012) |
| "Our data indicate that PrLZ protects prostate cancer cells from apoptosis and promotes tumor progression following androgen deprivation." | 1.37 | PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. ( Chang, LS; Chung, LW; He, D; Li, L; Wang, R; Wang, X; Wu, K; Xie, H; Xue, Y; Zeng, J; Zhang, D; Zhau, HE, 2011) |
| "Prostate cancer is dependent on androgens for growth in the initial stages where apoptosis is simultaneously inhibited." | 1.37 | Regulation of apoptosis by androgens in prostate cancer cells. ( Arnoldussen, YJ; Saatcioglu, F; Wang, L, 2011) |
| "We observed that human prostate cancer cells treated with MK591 undergo apoptosis within hours of treatment." | 1.36 | MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase. ( Ghosh, J; Myers, CE; Sarveswaran, S, 2010) |
| "PC3 and LNCaP prostate cancer cells were also sensitive to treatment with the PI3K inhibitor LY294002." | 1.36 | The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation. ( Belka, C; Eibl, HJ; Handrick, R; Jendrossek, V; Rudner, J; Ruiner, CE, 2010) |
| "Effective treatments for advanced prostate cancer are much needed." | 1.35 | Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors. ( Cheng, JQ; Chu, B; Djeu, J; Mohapatra, S; Pledger, WJ; Zhao, X, 2009) |
| "We cultured human prostate cancer cells (DU145 and PC-3 cells) and bladder cancer cells (EJ-1 and UM-UC-3 cells) with a PI3-kinase inhibitor, LY294002 for more than 6 weeks and cell proliferation was studied." | 1.35 | Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells. ( Kanda, S; Kanetake, H; Miyata, Y, 2009) |
| "Genistein is a phytoestrogen that has been reported to suppress the AKT signaling pathway in several malignancies." | 1.35 | Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. ( Dahiya, R; Hirata, H; Igawa, M; Kawamoto, K; Kikuno, N; Majid, S; Shiina, H; Tanaka, Y; Urakami, S, 2008) |
| "Treatment of human prostate cancer cells viz." | 1.34 | Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. ( Fu, P; Gupta, S; Hartman, DJ; Maclennan, GT; Resnick, MI; Shukla, S, 2007) |
| "The supernatant of PC-3 prostate cancer cells facilitated tube-like formation in TR-LE cells, and formation was inhibited by neutralising antibodies against FGF-2." | 1.34 | Tumour-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells. ( Koizumi, K; Matsuo, M; Saiki, I; Sakurai, H; Yamada, S, 2007) |
| "A critical factor in prostate cancer development and progression is the altered expression of apoptotic regulatory proteins which renders cells resistant to both hormone- and chemo-therapies." | 1.34 | Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. ( Fitzpatrick, JM; Gill, C; Morrissey, C; Walsh, SE; Watson, RW, 2007) |
| "Since CT/CTR expression in prostate cancers increases with tumor progression, the suppression of "CT System" may enhance the effectiveness of chemotherapy." | 1.33 | Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway. ( Shah, G; Thomas, S, 2005) |
| "Here, we evaluated the role of MCP-1 on prostate cancer (CaP) cell proliferation and invasion." | 1.33 | Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. ( Cai, Z; Galson, DL; George, DE; Liu, Y; Lu, Y; Melhem, MF; Xiao, G; Yao, Z; Zhang, J, 2006) |
| "The androgen-dependent prostate cancer cell line, LNCaP, expresses the EGFR as well as two additional members of the family; ErbB-2 and ErbB-3, which can be activated by neuregulin (NRG) isoforms." | 1.32 | Neuregulin promotes autophagic cell death of prostate cancer cells. ( Di-Segni, A; Lupowitz, Z; Pinkas-Kramarski, R; Tal-Or, P, 2003) |
| "However, different prostate cancer cell lines such as LNCaP and PC-3 display differential sensitivity to the apoptotic effect of PI3K inhibition in serum-free media, reflecting the heterogeneous nature of prostate cancer in apoptosis regulation." | 1.32 | Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. ( Chen, CS; Lin, HP; Rangnekar, VM; Tseng, PH; Yang, CC; Yang, YT, 2003) |
| "In advanced stages of prostate cancer, the phosphatidylinositol-3' kinase (PI3K)/Akt signaling cascade, one of the major survival pathways in the cell, is frequently constitutively activated due to mutation or loss of the tumor suppressor protein phosphatase and tensin homolog deleted on chromosome 10 (PTEN)." | 1.32 | Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. ( Bartsch, G; Culig, Z; Eder, IE; Klocker, H; Pfeil, K; Putz, T; Ramoner, R; Ueberall, F, 2004) |
| "PC3 and LNCaP human prostate cancer cell lines were exposed for 72 hours to rapamycin (mTOR inhibition), LY294002 (PI3K/AKT inhibition) and TGF-beta1 in a proliferation (WST-1) assay." | 1.32 | Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells. ( van der Poel, HG, 2004) |
| "Here we demonstrate that in human prostate cancer cells, basal-, growth factor-, and mitogen-induced expression of hypoxia-inducible factor 1 (HIF-1) alpha, the regulated subunit of the transcription factor HIF-1, is blocked by LY294002 and rapamycin, inhibitors of PI3K and FRAP, respectively." | 1.31 | Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. ( Chiles, K; Feldser, D; Georgescu, MM; Hanrahan, C; Laughner, E; Semenza, GL; Simons, JW; Zhong, H, 2000) |
| "Some prostate cancer cells express constitutively active Akt/protein kinase B due to a complete loss of lipid phosphatase PTEN gene, a negative regulator of phosphatidylinositol 3-kinase pathway." | 1.31 | Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance. ( Chen, X; Gim, S; Lee, C; Nwokorie, C; Onwudiwe, N; Pandey, SK; Robinson, H; Srivastava, RK; Thakkar, H; Tyan, F, 2001) |
| "Some prostate cancer cells express high levels of Akt due to lack of active lipid phosphatase PTEN, a negative regulator of PI-3 kinase pathway, which may be responsible for drug resistance." | 1.31 | Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. ( Chen, X; Gim, S; Lee, C; Nwokorie, C; Onwudiwe, N; Pandey, SK; Robinson, H; Srivastava, RK; Thakkar, H; Tyan, F, 2001) |
| "The mechanisms by which prostate cancer (PCa) cells progress to a hormone refractory state are poorly understood." | 1.31 | Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. ( Huang, H; Murillo, H; Schmidt, LJ; Smith, DI; Tindall, DJ, 2001) |
| "We observed that LNCaP prostate cancer cells failed to undergo apoptosis induced by cytochrome c microinjections." | 1.31 | Smac is required for cytochrome c-induced apoptosis in prostate cancer LNCaP cells. ( Behnam, M; Carson, JP; Du, C; Hunt, DF; Kulik, G; Sutton, JN; Wang, X; Weber, MJ, 2002) |
| "Using LNCaP prostate cancer cells as an experimental paradigm of FAS-overexpressing PTEN-null cancer cells, we demonstrate that LY294002, an inhibitor of the PI3k pathway causes a dramatic decrease in FAS protein expression." | 1.31 | Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. ( De Schrijver, E; Heyns, W; Swinnen, JV; Van de Sande, T; Verhoeven, G, 2002) |
| "PI3K/Akt plays a critical role in prostate cancer cell growth and survival." | 1.31 | Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. ( Chuang, WW; Sharma, M; Sun, Z, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.06) | 18.2507 |
| 2000's | 59 (62.77) | 29.6817 |
| 2010's | 32 (34.04) | 24.3611 |
| 2020's | 2 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Ryu, BJ | 1 |
| Baek, SH | 1 |
| Kim, J | 1 |
| Bae, SJ | 1 |
| Chang, SY | 1 |
| Heo, JN | 1 |
| Lee, H | 1 |
| Lee, SY | 1 |
| Kim, SH | 1 |
| Melchini, A | 1 |
| Needs, PW | 1 |
| Mithen, RF | 1 |
| Traka, MH | 1 |
| Sekino, Y | 1 |
| Han, X | 1 |
| Kawaguchi, T | 1 |
| Babasaki, T | 1 |
| Goto, K | 1 |
| Inoue, S | 1 |
| Hayashi, T | 1 |
| Teishima, J | 1 |
| Shiota, M | 1 |
| Yasui, W | 1 |
| Matsubara, A | 1 |
| Liu, CM | 1 |
| Wu, Z | 3 |
| Pan, B | 1 |
| An, L | 1 |
| Zhu, C | 1 |
| Zhou, J | 1 |
| Jiang, Y | 1 |
| Watanabe, H | 1 |
| Kawakami, A | 1 |
| Sato, R | 1 |
| Watanabe, K | 1 |
| Matsushita, Y | 1 |
| Miyake, H | 1 |
| Steely, AM | 1 |
| Willoughby, JA | 1 |
| Sundar, SN | 1 |
| Aivaliotis, VI | 1 |
| Firestone, GL | 1 |
| Zeng, Y | 1 |
| Yang, Y | 1 |
| Li, X | 1 |
| Tang, Y | 1 |
| Yu, F | 1 |
| Sun, Y | 1 |
| Huang, F | 1 |
| Chen, Y | 2 |
| Yang, Z | 1 |
| Ding, G | 1 |
| Shao, G | 1 |
| Liu, Y | 2 |
| Ma, T | 1 |
| Zhang, L | 1 |
| Yuan, M | 1 |
| Zhao, S | 1 |
| Kretschmer, A | 1 |
| Zhang, F | 1 |
| Somasekharan, SP | 1 |
| Tse, C | 1 |
| Leachman, L | 1 |
| Gleave, A | 1 |
| Li, B | 2 |
| Asmaro, I | 1 |
| Huang, T | 1 |
| Kotula, L | 1 |
| Sorensen, PH | 1 |
| Gleave, ME | 2 |
| Sung, CH | 1 |
| Im, HJ | 1 |
| Park, N | 1 |
| Kwon, Y | 1 |
| Shin, S | 1 |
| Ye, DJ | 1 |
| Cho, NH | 1 |
| Park, YS | 1 |
| Choi, HK | 1 |
| Kim, D | 1 |
| Chun, YJ | 1 |
| Rybalkina, EIu | 1 |
| Stromskaia, TP | 1 |
| Ovchinnikov, LP | 1 |
| Stavrovskaia, AA | 1 |
| Liu, L | 1 |
| Dong, X | 1 |
| Fateye, B | 1 |
| Wan, A | 1 |
| Yang, X | 1 |
| Myers, K | 1 |
| Chen, B | 1 |
| Liu, Z | 1 |
| Zhu, G | 1 |
| Getzenberg, RH | 1 |
| Veltri, RW | 1 |
| Zhifang, M | 1 |
| Liang, W | 1 |
| Wei, Z | 1 |
| Bin, H | 1 |
| Rui, T | 1 |
| Nan, W | 1 |
| Shuhai, Z | 1 |
| Flores, ML | 1 |
| Castilla, C | 1 |
| Gasca, J | 1 |
| Medina, R | 1 |
| Pérez-Valderrama, B | 1 |
| Romero, F | 1 |
| Japón, MA | 1 |
| Sáez, C | 1 |
| Wang, S | 1 |
| Yang, Q | 1 |
| Fung, KM | 1 |
| Lin, HK | 2 |
| Mohapatra, S | 1 |
| Chu, B | 1 |
| Zhao, X | 1 |
| Djeu, J | 1 |
| Cheng, JQ | 1 |
| Pledger, WJ | 1 |
| Kanda, S | 1 |
| Kanetake, H | 2 |
| Miyata, Y | 1 |
| Chu, JH | 1 |
| Yu, S | 1 |
| Hayward, SW | 1 |
| Chan, FL | 1 |
| Prawettongsopon, C | 1 |
| Asawakarn, S | 1 |
| Suthiphongchai, T | 1 |
| Gan, L | 1 |
| Chen, S | 1 |
| Wang, Y | 2 |
| Watahiki, A | 1 |
| Bohrer, L | 1 |
| Sun, Z | 2 |
| Huang, H | 2 |
| Sarveswaran, S | 1 |
| Myers, CE | 1 |
| Ghosh, J | 1 |
| Axanova, LS | 1 |
| Chen, YQ | 1 |
| McCoy, T | 1 |
| Sui, G | 1 |
| Cramer, SD | 1 |
| Wang, L | 4 |
| Jin, Y | 1 |
| Arnoldussen, YJ | 2 |
| Jonson, I | 1 |
| Qu, S | 1 |
| Maelandsmo, GM | 1 |
| Kristian, A | 1 |
| Risberg, B | 1 |
| Waehre, H | 1 |
| Danielsen, HE | 1 |
| Saatcioglu, F | 2 |
| Rudner, J | 1 |
| Ruiner, CE | 1 |
| Handrick, R | 1 |
| Eibl, HJ | 1 |
| Belka, C | 1 |
| Jendrossek, V | 1 |
| Chen, Q | 1 |
| Ganapathy, S | 1 |
| Singh, KP | 1 |
| Shankar, S | 1 |
| Srivastava, RK | 3 |
| Ha, S | 1 |
| Ruoff, R | 1 |
| Kahoud, N | 1 |
| Franke, TF | 1 |
| Logan, SK | 1 |
| Zhang, D | 1 |
| He, D | 1 |
| Xue, Y | 1 |
| Wang, R | 1 |
| Wu, K | 1 |
| Xie, H | 1 |
| Zeng, J | 1 |
| Wang, X | 2 |
| Zhau, HE | 1 |
| Chung, LW | 1 |
| Chang, LS | 1 |
| Li, L | 1 |
| Wen, X | 1 |
| Chao, C | 1 |
| Ives, K | 1 |
| Hellmich, MR | 1 |
| Jin, L | 1 |
| Zhang, Q | 1 |
| Guo, R | 1 |
| Wang, J | 1 |
| Wan, R | 1 |
| Zhang, R | 1 |
| Xu, Y | 1 |
| Li, S | 1 |
| Misra, UK | 1 |
| Pizzo, SV | 1 |
| Cortés, MA | 1 |
| Cariaga-Martinez, AE | 1 |
| Lobo, MV | 1 |
| Martín Orozco, RM | 1 |
| Motiño, O | 1 |
| Rodríguez-Ubreva, FJ | 1 |
| Angulo, J | 1 |
| López-Ruiz, P | 1 |
| Colás, B | 1 |
| Tilli, TM | 1 |
| Mello, KD | 1 |
| Ferreira, LB | 1 |
| Matos, AR | 1 |
| Accioly, MT | 1 |
| Faria, PA | 1 |
| Bellahcène, A | 1 |
| Castronovo, V | 1 |
| Gimba, ER | 1 |
| Collak, FK | 1 |
| Yagiz, K | 1 |
| Luthringer, DJ | 1 |
| Erkaya, B | 1 |
| Cinar, B | 1 |
| Mediwala, SN | 1 |
| Sun, H | 1 |
| Szafran, AT | 1 |
| Hartig, SM | 1 |
| Sonpavde, G | 1 |
| Hayes, TG | 1 |
| Thiagarajan, P | 1 |
| Mancini, MA | 1 |
| Marcelli, M | 1 |
| Baiz, D | 1 |
| Pinder, TA | 1 |
| Hassan, S | 1 |
| Karpova, Y | 1 |
| Salsbury, F | 1 |
| Welker, ME | 1 |
| Kulik, G | 3 |
| Sheth, S | 1 |
| Jajoo, S | 1 |
| Kaur, T | 1 |
| Mukherjea, D | 1 |
| Sheehan, K | 1 |
| Rybak, LP | 1 |
| Ramkumar, V | 1 |
| Plymate, SR | 1 |
| Haugk, KH | 1 |
| Sprenger, CC | 1 |
| Nelson, PS | 1 |
| Tennant, MK | 1 |
| Zhang, Y | 1 |
| Oberley, LW | 1 |
| Zhong, W | 1 |
| Drivdahl, R | 1 |
| Oberley, TD | 1 |
| Tal-Or, P | 1 |
| Di-Segni, A | 1 |
| Lupowitz, Z | 1 |
| Pinkas-Kramarski, R | 1 |
| Tiwari, G | 1 |
| Sakaue, H | 1 |
| Pollack, JR | 1 |
| Roth, RA | 1 |
| Liao, X | 1 |
| Thrasher, JB | 1 |
| Pelling, J | 1 |
| Holzbeierlein, J | 1 |
| Sang, QX | 1 |
| Yang, CC | 1 |
| Lin, HP | 1 |
| Chen, CS | 2 |
| Yang, YT | 1 |
| Tseng, PH | 1 |
| Rangnekar, VM | 2 |
| Tørring, N | 1 |
| Dagnaes-Hansen, F | 1 |
| Sørensen, BS | 1 |
| Nexø, E | 1 |
| Hynes, NE | 1 |
| Mabjeesh, NJ | 1 |
| Willard, MT | 1 |
| Frederickson, CE | 1 |
| Zhong, H | 2 |
| Simons, JW | 2 |
| Shimada, K | 1 |
| Nakamura, M | 1 |
| Ishida, E | 1 |
| Kishi, M | 1 |
| Matsuyoshi, S | 1 |
| Konishi, N | 1 |
| Pfeil, K | 1 |
| Eder, IE | 1 |
| Putz, T | 1 |
| Ramoner, R | 1 |
| Culig, Z | 1 |
| Ueberall, F | 1 |
| Bartsch, G | 1 |
| Klocker, H | 1 |
| Gao, N | 1 |
| Shen, L | 1 |
| Zhang, Z | 1 |
| Leonard, SS | 1 |
| He, H | 1 |
| Zhang, XG | 1 |
| Shi, X | 1 |
| Jiang, BH | 2 |
| van der Poel, HG | 1 |
| Lee, TJ | 1 |
| Sartor, O | 1 |
| Luftig, RB | 1 |
| Koochekpour, S | 1 |
| Schwarzer, R | 1 |
| Tondera, D | 1 |
| Arnold, W | 1 |
| Giese, K | 1 |
| Klippel, A | 1 |
| Kaufmann, J | 1 |
| Kim, BY | 1 |
| Kim, KA | 1 |
| Kwon, O | 1 |
| Kim, SO | 1 |
| Kim, MS | 1 |
| Kim, BS | 1 |
| Oh, WK | 1 |
| Kim, GD | 1 |
| Jung, M | 1 |
| Ahn, JS | 1 |
| Hu, H | 1 |
| Jiang, C | 1 |
| Li, G | 1 |
| Lü, J | 1 |
| Le Page, C | 1 |
| Koumakpayi, IH | 1 |
| Lessard, L | 1 |
| Saad, F | 1 |
| Mes-Masson, AM | 1 |
| Poh, TW | 1 |
| Pervaiz, S | 1 |
| Yang, L | 2 |
| Xie, S | 1 |
| Jamaluddin, MS | 1 |
| Altuwaijri, S | 1 |
| Ni, J | 1 |
| Kim, E | 1 |
| Chen, YT | 1 |
| Hu, YC | 1 |
| Chuang, KH | 1 |
| Wu, CT | 1 |
| Chang, C | 2 |
| Goswami, A | 1 |
| Burikhanov, R | 1 |
| de Thonel, A | 1 |
| Fujita, N | 1 |
| Goswami, M | 1 |
| Zhao, Y | 1 |
| Eriksson, JE | 1 |
| Tsuruo, T | 1 |
| Wells, CM | 1 |
| Ahmed, T | 1 |
| Masters, JR | 1 |
| Jones, GE | 1 |
| Thomas, S | 1 |
| Shah, G | 1 |
| Gottschalk, AR | 1 |
| Doan, A | 1 |
| Nakamura, JL | 1 |
| Stokoe, D | 1 |
| Haas-Kogan, DA | 1 |
| Howells, LM | 1 |
| Hudson, EA | 1 |
| Manson, MM | 1 |
| Festuccia, C | 2 |
| Muzi, P | 2 |
| Millimaggi, D | 2 |
| Biordi, L | 1 |
| Gravina, GL | 2 |
| Speca, S | 1 |
| Angelucci, A | 1 |
| Dolo, V | 2 |
| Vicentini, C | 2 |
| Bologna, M | 2 |
| Hughes-Fulford, M | 1 |
| Li, CF | 1 |
| Boonyaratanakornkit, J | 1 |
| Sayyah, S | 1 |
| Montagnani Marelli, M | 1 |
| Moretti, RM | 1 |
| Procacci, P | 1 |
| Motta, M | 1 |
| Limonta, P | 1 |
| Hakariya, T | 1 |
| Shida, Y | 1 |
| Sakai, H | 1 |
| Igawa, T | 1 |
| Nie, D | 1 |
| Krishnamoorthy, S | 1 |
| Jin, R | 1 |
| Tang, K | 1 |
| Qiao, Y | 1 |
| Zacharek, A | 1 |
| Guo, Y | 1 |
| Milanini, J | 1 |
| Pages, G | 1 |
| Honn, KV | 1 |
| Bertram, J | 1 |
| Peacock, JW | 1 |
| Tan, C | 1 |
| Mui, AL | 1 |
| Chung, SW | 1 |
| Dedhar, S | 1 |
| Cox, ME | 1 |
| Ong, CJ | 1 |
| Lu, Y | 1 |
| Cai, Z | 1 |
| Galson, DL | 1 |
| Xiao, G | 1 |
| George, DE | 1 |
| Melhem, MF | 1 |
| Yao, Z | 1 |
| Zhang, J | 1 |
| Renner, O | 1 |
| Fominaya, J | 1 |
| Alonso, S | 1 |
| Blanco-Aparicio, C | 1 |
| Leal, JF | 1 |
| Carnero, A | 1 |
| Shukla, S | 1 |
| Maclennan, GT | 1 |
| Hartman, DJ | 1 |
| Fu, P | 1 |
| Resnick, MI | 1 |
| Gupta, S | 1 |
| Matsuo, M | 1 |
| Yamada, S | 1 |
| Koizumi, K | 1 |
| Sakurai, H | 1 |
| Saiki, I | 1 |
| Liu, S | 1 |
| Vinall, RL | 1 |
| Tepper, C | 1 |
| Shi, XB | 1 |
| Xue, LR | 1 |
| Ma, AH | 1 |
| Wang, LY | 1 |
| Fitzgerald, LD | 1 |
| Gandour-Edwards, R | 1 |
| deVere White, RW | 1 |
| Kung, HJ | 2 |
| Gill, C | 1 |
| Walsh, SE | 1 |
| Morrissey, C | 1 |
| Fitzpatrick, JM | 1 |
| Watson, RW | 1 |
| Fang, J | 1 |
| Ding, M | 1 |
| Liu, LZ | 1 |
| Albrecht, DS | 1 |
| Clubbs, EA | 1 |
| Ferruzzi, M | 1 |
| Bomser, JA | 1 |
| Wang, YX | 1 |
| Shi, YH | 1 |
| Gong, LH | 1 |
| Li, Y | 1 |
| Heng, WJ | 1 |
| You, JF | 1 |
| Zhong, HH | 1 |
| Fang, WG | 1 |
| Jia, L | 1 |
| Yu, W | 1 |
| Wang, P | 1 |
| Sanders, BG | 1 |
| Kline, K | 1 |
| Gioeli, D | 1 |
| Conaway, M | 1 |
| Weber, MJ | 3 |
| Theodorescu, D | 1 |
| Cornforth, AN | 1 |
| Davis, JS | 1 |
| Khanifar, E | 1 |
| Nastiuk, KL | 1 |
| Krolewski, JJ | 1 |
| Kikuno, N | 1 |
| Shiina, H | 1 |
| Urakami, S | 1 |
| Kawamoto, K | 1 |
| Hirata, H | 1 |
| Tanaka, Y | 1 |
| Majid, S | 1 |
| Igawa, M | 1 |
| Dahiya, R | 1 |
| Xue, LY | 1 |
| Qiu, Y | 1 |
| He, J | 1 |
| Oleinick, NL | 1 |
| Chiles, K | 1 |
| Feldser, D | 1 |
| Laughner, E | 1 |
| Hanrahan, C | 1 |
| Georgescu, MM | 1 |
| Semenza, GL | 1 |
| Wen, Y | 1 |
| Hu, MC | 1 |
| Makino, K | 1 |
| Spohn, B | 1 |
| Bartholomeusz, G | 1 |
| Yan, DH | 1 |
| Hung, MC | 1 |
| Carson, JP | 2 |
| Vomastek, T | 1 |
| Overman, K | 1 |
| Gooch, BD | 1 |
| Srinivasula, S | 1 |
| Alnemri, E | 1 |
| Nunez, G | 1 |
| Yeh, S | 1 |
| Kang, HY | 1 |
| Thakkar, H | 2 |
| Chen, X | 2 |
| Tyan, F | 2 |
| Gim, S | 2 |
| Robinson, H | 2 |
| Lee, C | 2 |
| Pandey, SK | 2 |
| Nwokorie, C | 2 |
| Onwudiwe, N | 2 |
| Murillo, H | 1 |
| Schmidt, LJ | 1 |
| Smith, DI | 1 |
| Tindall, DJ | 1 |
| Behnam, M | 1 |
| Sutton, JN | 1 |
| Du, C | 1 |
| Hunt, DF | 1 |
| Van de Sande, T | 1 |
| De Schrijver, E | 1 |
| Heyns, W | 1 |
| Verhoeven, G | 1 |
| Swinnen, JV | 1 |
| Sharma, M | 1 |
| Chuang, WW | 1 |
94 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Cancer of Prostate
| Article | Year |
|---|---|
Anti-androgen receptor activity of apoptotic CK2 inhibitor CX4945 in human prostate cancer LNCap cells.
Topics: Androgen Antagonists; Antineoplastic Agents; Apoptosis; Casein Kinase II; Cell Line, Tumor; Humans; | 2012 |
Enhanced in vitro biological activity of synthetic 2-(2-pyridyl) ethyl isothiocyanate compared to natural 4-(methylsulfinyl) butyl isothiocyanate.
Topics: Anticarcinogenic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Brassica; Cell Proliferati | 2012 |
TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromones; Docetaxel; Drug Resistance, Neoplasm; Enzyme Inh | 2019 |
The antiandrogenic effect of neferine, liensinine, and isoliensinine by inhibiting 5-α-reductase and androgen receptor expression via PI3K/AKT signaling pathway in prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Amino Acid Chloromethyl Ketones; Androgen Antagonists; Androgen Recept | 2021 |
Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Topics: Animals; Antineoplastic Agents; Chromones; Docetaxel; Drug Resistance, Neoplasm; Humans; Ki-67 Antig | 2021 |
Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
Topics: Artemisinins; Cell Line, Tumor; Chromones; Down-Regulation; Enzyme Inhibitors; Humans; Kallikreins; | 2017 |
Piperine depresses the migration progression via downregulating the Akt/mTOR/MMP‑9 signaling pathway in DU145 cells.
Topics: Alkaloids; Apoptosis; Benzodioxoles; Cell Line, Tumor; Cell Movement; Chromones; Humans; Male; Matri | 2018 |
Inhibition of Prostate Cancer DU-145 Cells Proliferation by
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Dru | 2018 |
GCN5 inhibition prevents IL-6-induced prostate cancer metastases through PI3K/PTEN/Akt signaling by inactivating Egr-1.
Topics: Cell Movement; Cell Proliferation; Chromones; Early Growth Response Protein 1; Epithelial-Mesenchyma | 2018 |
Stress-induced tunneling nanotubes support treatment adaptation in prostate cancer.
Topics: Actin Cytoskeleton; Actins; Androgen Receptor Antagonists; Biological Transport; Cell Communication; | 2019 |
Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by insulin-like growth factor II.
Topics: 17-Hydroxysteroid Dehydrogenases; Androstadienes; Boronic Acids; Bortezomib; Cell Line, Tumor; Chrom | 2013 |
[Connection of intracellular protein YB-1 localization in cell cultures of human tumors with multidrug resistance].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2013 |
Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
Topics: Androstadienes; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Gene Expression Regulation, Neoplast | 2014 |
Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3K pathway inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Survival; Chromones; Endothelial Cells; H | 2015 |
The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
Topics: Cell Line, Tumor; Cell Survival; Chromones; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fl | 2015 |
The androgen receptor plays a suppressive role in epithelial- mesenchymal transition of human prostate cancer stem progenitor cells.
Topics: Azacitidine; Cell Line, Tumor; Cell Self Renewal; Chromans; Chromones; Decitabine; Drug Synergism; E | 2015 |
Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aurora Kinase A; beta Catenin; Cell Cycle Checkpoints; | 2016 |
AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Cell Line, Tumor; Cell Prol | 2008 |
Apoptosis of metastatic prostate cancer cells by a combination of cyclin-dependent kinase and AKT inhibitors.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Caspase 9; Cell Line, Tumor; Chlorp | 2009 |
Loss of PTEN function may account for reduced proliferation pathway sensitivity to LY294002 in human prostate and bladder cancer cells.
Topics: Cell Division; Cell Line, Tumor; Chromones; Cloning, Molecular; Enzyme Inhibitors; Humans; Liposomes | 2009 |
Development of a three-dimensional culture model of prostatic epithelial cells and its use for the study of epithelial-mesenchymal transition and inhibition of PI3K pathway in prostate cancer.
Topics: Cell Differentiation; Cell Line; Cell Transformation, Neoplastic; Chromones; Collagen; Culture Techn | 2009 |
Suppression of prometastatic phenotype of highly metastatic androgen-independent rat prostate cancer MLL cell line by PI3K inhibitor LY294002.
Topics: Adenocarcinoma; Androgens; Animals; Cell Movement; Chromones; Enzyme Inhibitors; Extracellular Signa | 2009 |
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Topics: Androgen Receptor Antagonists; Androgens; Animals; Antineoplastic Agents; Antineoplastic Agents, Phy | 2009 |
MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase.
Topics: Apoptosis; Cell Survival; Chromones; Drug Synergism; Enzyme Inhibitors; Humans; Indoles; Lipoxygenas | 2010 |
1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cellu | 2010 |
STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer.
Topics: Amino Acid Sequence; Animals; Apoptosis; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Chloro | 2010 |
The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Death; Cell Line, Tumor; Chromones; Humans; Male; | 2010 |
Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells.
Topics: Androstadienes; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; F | 2010 |
Androgen receptor levels are upregulated by Akt in prostate cancer.
Topics: Androgens; Animals; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 2; Chromones; Histones; H | 2011 |
PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway.
Topics: Androgens; Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Charcoal; Chromones; Dextrans; E | 2011 |
Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells.
Topics: Active Transport, Cell Nucleus; Bombesin; Cell Line, Tumor; Chromones; Cyclooxygenase 2; Dinoproston | 2011 |
Different effects of corticotropin-releasing factor and urocortin 2 on apoptosis of prostate cancer cells in vitro.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Chromones; Corticotropin-Releasing | 2011 |
Regulation of apoptosis by androgens in prostate cancer cells.
Topics: Androgens; Apoptosis; Cell Line, Tumor; Chromones; DNA Fragmentation; Flow Cytometry; Humans; In Sit | 2011 |
Upregulation of mTORC2 activation by the selective agonist of EPAC, 8-CPT-2Me-cAMP, in prostate cancer cells: assembly of a multiprotein signaling complex.
Topics: Adaptor Proteins, Signal Transducing; Carrier Proteins; Cell Line, Tumor; Chromones; Cyclic AMP; Cyc | 2012 |
EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
Topics: Androgens; Androstadienes; Cell Differentiation; Cell Line, Tumor; Cell Survival; Chromogranin A; Ch | 2012 |
Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chromon | 2012 |
Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Chromones; HEK293 Cells; HeLa Cells; Hum | 2012 |
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.
Topics: Androstadienes; Castration; Cell Line, Tumor; Chromones; Disease Progression; Forkhead Box Protein O | 2013 |
Synthesis and characterization of a novel prostate cancer-targeted phosphatidylinositol-3-kinase inhibitor prodrug.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chemistry Techniques, Synth | 2012 |
Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chro | 2012 |
Increased manganese superoxide dismutase (SOD-2) is part of the mechanism for prostate tumor suppression by Mac25/insulin-like growth factor binding-protein-related protein-1.
Topics: Adenocarcinoma; Animals; Apoptosis; beta-Galactosidase; Carrier Proteins; Cell Line, Transformed; Ce | 2003 |
Neuregulin promotes autophagic cell death of prostate cancer cells.
Topics: Adenine; Amino Acid Chloromethyl Ketones; Autophagy; Cell Death; Cell Division; Chromones; Cysteine | 2003 |
Gene expression profiling in prostate cancer cells with Akt activation reveals Fra-1 as an Akt-inducible gene.
Topics: Aryl Hydrocarbon Hydroxylases; Cell Line, Tumor; Chromones; Cytochrome P-450 CYP1B1; Enzyme Activati | 2003 |
Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer.
Topics: Cell Movement; Chromones; Enzyme Inhibitors; Humans; Hydroxamic Acids; Male; Matrix Metalloproteinas | 2003 |
Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells.
Topics: Apoptosis; bcl-X Protein; Blotting, Western; Cell Survival; Chromones; Culture Media, Serum-Free; Cy | 2003 |
ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.
Topics: Androgens; Apoptosis; Cell Division; Chromones; Drug Interactions; Enzyme Inhibitors; Epidermal Grow | 2003 |
Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3'-kinase/protein kinase B in prostate cancer cells.
Topics: Androgens; Blotting, Western; Cell Line, Tumor; Chromones; Culture Media, Conditioned; Dihydrotestos | 2003 |
The molecular mechanism of sensitization to Fas-mediated apoptosis by 2-methoxyestradiol in PC3 prostate cancer cells.
Topics: 2-Methoxyestradiol; Apoptosis; Arabidopsis Proteins; Carrier Proteins; CASP8 and FADD-Like Apoptosis | 2004 |
Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Topics: Androgen Antagonists; Apoptosis; Cell Line, Tumor; Chromones; Drug Resistance; Enzyme Inhibitors; Ep | 2004 |
Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells.
Topics: Androstadienes; Arsenites; Cell Line, Tumor; Chromones; DNA-Binding Proteins; Humans; Hypoxia-Induci | 2004 |
Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells.
Topics: Antibiotics, Antineoplastic; Cell Division; Cell Line, Tumor; Chromones; Drug Interactions; Flutamid | 2004 |
Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Chromones; Culture Media, Serum-Free; Enzyme A | 2004 |
REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase.
Topics: Apoptosis; Cell Hypoxia; Cell Line, Tumor; Chromones; Cobalt; Dimethyl Sulfoxide; Gene Expression; H | 2005 |
NF-kappaB inhibition radiosensitizes Ki-Ras-transformed cells to ionizing radiation.
Topics: Apoptosis; Cell Line, Transformed; Cell Line, Tumor; Chromones; Dose-Response Relationship, Radiatio | 2005 |
PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells.
Topics: Apoptosis; Butadienes; Caspases; Cell Line, Tumor; Chromones; Humans; Kinetics; Male; Mitogen-Activa | 2005 |
Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells.
Topics: Blotting, Western; Casein Kinase II; Cell Line, Tumor; Chromones; Electrophoretic Mobility Shift Ass | 2005 |
LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway.
Topics: Apoptosis; Caspase Inhibitors; Catalase; Cell Growth Processes; Cell Line, Tumor; Chromones; Enzyme | 2005 |
Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.
Topics: Androgen Receptor Antagonists; Apoptosis; Cell Line, Tumor; Chromatin Immunoprecipitation; Chromones | 2005 |
Binding and phosphorylation of par-4 by akt is essential for cancer cell survival.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Line; Cell Survival; Chromones; Enzyme Activation; En | 2005 |
Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering.
Topics: Actins; Animals; Blotting, Western; Cadherins; Cell Adhesion; Cell Line, Tumor; Chromones; Cytoskele | 2005 |
Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway.
Topics: Antineoplastic Agents; Apoptosis; Calcitonin; Cell Line, Tumor; Chromones; Enzyme Activation; Enzyme | 2005 |
Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism.
Topics: Apoptosis; Chromones; Class I Phosphatidylinositol 3-Kinases; Enzyme Inhibitors; Humans; Male; Morph | 2005 |
Inhibition of phosphatidylinositol 3-kinase/protein kinase B signaling is not sufficient to account for indole-3-carbinol-induced apoptosis in some breast and prostate tumor cells.
Topics: Antioxidants; Apoptosis; Blotting, Western; Breast Neoplasms; Chromones; Drug Combinations; Enzyme I | 2005 |
Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, | 2005 |
Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer.
Topics: Arachidonic Acid; Cell Growth Processes; Chromones; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; E | 2006 |
Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling.
Topics: Actins; Androgens; Antibodies; Butadienes; Cell Line, Tumor; Cell Movement; Chromones; Cytoskeleton; | 2006 |
EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells.
Topics: Androgens; Cell Line, Tumor; Chromones; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Ge | 2006 |
Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Arachidonate 12-Lipoxygenase; Cell Line, Tumor; Cell Mov | 2006 |
Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antibodies; Apoptosis; Cell Line, Tumor; Chromones; Enzyme Inh | 2006 |
Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion.
Topics: Cell Line; Cell Line, Tumor; Cell Proliferation; Chemokine CCL2; Chromones; Epithelial Cells; Gene E | 2006 |
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.
Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Chromones; Class I Phosphatidylinositol 3-Kinases; Enzym | 2007 |
Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Topics: Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Dose-Response Rel | 2007 |
Tumour-derived fibroblast growth factor-2 exerts lymphangiogenic effects through Akt/mTOR/p70S6kinase pathway in rat lymphatic endothelial cells.
Topics: Animals; Cell Communication; Chromones; Endothelial Cells; Enzyme Inhibitors; Fibroblast Growth Fact | 2007 |
Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway.
Topics: beta Catenin; Cell Nucleus; Chromones; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulat | 2008 |
Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Chromones; Dose-Response Relationshi | 2007 |
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Chick Embryo; Chromones; Dose-Response Relations | 2007 |
Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation.
Topics: Anticarcinogenic Agents; Catechin; Cell Line; Cell Line, Tumor; Cell Proliferation; Chromones; Enzym | 2008 |
[P2Y purinergic receptor activated PI-3K/Akt signaling pathway in regulation of growth and invasion of prostatic cancer].
Topics: Adenylyl Imidodiphosphate; Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2007 |
In vivo and in vitro studies of anticancer actions of alpha-TEA for human prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Li | 2008 |
Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
Topics: Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; | 2008 |
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; ErbB Receptors; Gefi | 2008 |
FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells.
Topics: Androgens; Apoptosis; Binding Sites; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tu | 2008 |
Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.
Topics: Acetylation; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Wester | 2008 |
Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin.
Topics: Apoptosis; Carcinoma; Cell Survival; Chromones; DNA Fragmentation; Enzyme Inhibitors; Humans; Male; | 1999 |
Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics.
Topics: Carrier Proteins; Chromones; Culture Media, Serum-Free; DNA-Binding Proteins; Endothelial Growth Fac | 2000 |
HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway.
Topics: Amino Acid Sequence; Animals; Blotting, Western; Cell Division; Cell Line; Cell Survival; Chromones; | 2000 |
Tumor necrosis factor alpha induces BID cleavage and bypasses antiapoptotic signals in prostate cancer LNCaP cells.
Topics: Apoptosis; BH3 Interacting Domain Death Agonist Protein; Carrier Proteins; Caspase 9; Caspases; Chro | 2001 |
Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.
Topics: Amino Acid Substitution; Androgen Receptor Antagonists; Apoptosis; Chromones; Dihydrotestosterone; E | 2001 |
Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance.
Topics: Androstadienes; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Blotting, Western; Caspase | 2001 |
Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer.
Topics: Androstadienes; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; BH3 Interacting Domain Deat | 2001 |
Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state.
Topics: Androgen Antagonists; Androgens; Cell Cycle Proteins; Cell Division; Cell Survival; Chromones; Cultu | 2001 |
Smac is required for cytochrome c-induced apoptosis in prostate cancer LNCaP cells.
Topics: Amino Acid Sequence; Animals; Apoptosis; Apoptosis Regulatory Proteins; Carrier Proteins; Caspase In | 2002 |
Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells.
Topics: Adenocarcinoma; Chromones; Enzyme Inhibitors; Fatty Acid Synthases; Humans; Male; Morpholines; Phosp | 2002 |
Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation.
Topics: Androgens; beta Catenin; Calcium-Calmodulin-Dependent Protein Kinases; Cell Nucleus; Chromones; Cyto | 2002 |